Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | TYR | P14679 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280675 | 0.93 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2280674 | 0.93 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL30676338 | 0.91 | CA12 (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL3065424 | 0.91 | CA12 (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2631340 | 0.91 | CA12 (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2614742 | 0.89 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL31380287 | 0.89 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL4084338 | 0.89 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL13256239 | 0.89 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL289952 | 0.88 | TTR (0.54) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013760-B2 | Polyguanidine polymers and methods of use thereof | SEALIFE PHARMA GMBH (AT) | 2021-05-25 | — | — | US | disclosed |
| US-20190269719-A1 | POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF | SEALIFE PHARMA GMBH (AT) | 2019-09-05 | — | — | US | disclosed |
| US-10335431-B2 | Method for producing polyguanidines | SEALIFE PHARMA GMBH (AT) | 2019-07-02 | — | — | US | disclosed |
| EP-3174848-B1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2018-08-01 | — | — | EP | disclosed |
| US-20170224723-A1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2017-08-10 | — | — | US | disclosed |
| US-20170224723-A1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2017-08-10 | — | — | US | disclosed |
| WO-2016015081-A9 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016015081-A1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2016-02-04 | — | — | WO | disclosed |
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335431-B2 | Method for producing polyguanidines | GDA, PARG, ADAR | TTR 4768/4885APP 4326/4885PTPN1 3304/4885 |
| US-20190269719-A1 | POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF | PUF60, PARG, ALG1 | TTR 2518/4885APP 3448/4885PTPN1 2337/4885 |
| US-11013760-B2 | Polyguanidine polymers and methods of use thereof | PUF60, PARG, ALG1 | TTR 2518/4885APP 3448/4885PTPN1 2337/4885 |
| US-20170224723-A1 | METHOD FOR PRODUCING POLYGUANIDINES | GDA, PARG, ADAR | TTR 4768/4885APP 4326/4885PTPN1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.